Journal article
Phase II study of Triapine® in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161)
Abstract
Triapine® is a novel small molecule ribonucleotide reductase inhibitor that showed activity in renal cell carcinoma (RCC) cell lines. Evaluating new agents with novel mechanisms remains of interest for patients with incurable RCC. This was a single-arm, multicentre phase II trial where Triapine was given at a schedule of 96 mg/m2 2-h infusion daily × 4 repeated every 2 weeks in patients with recurrent RCC. A median of four cycles of Triapine …
Authors
Knox JJ; Hotte SJ; Kollmannsberger C; Winquist E; Fisher B; Eisenhauer EA
Journal
Investigational New Drugs, Vol. 25, No. 5, pp. 471–477
Publisher
Springer Nature
Publication Date
October 2007
DOI
10.1007/s10637-007-9044-9
ISSN
0167-6997